MCID: TNG003
MIFTS: 58

Tongue Cancer malady

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Tongue Cancer

Aliases & Descriptions for Tongue Cancer:

Name: Tongue Cancer 12 50 52 14
Tongue Carcinoma 50 52 69
Malignant Neoplasm of Tongue 12 69
Tongue Neoplasms 42 69
Malignant Neoplasm of Anterior Two-Thirds of Tongue, Part Unspecified 12
Malignant Neoplasm of Tip and/or Lateral Border of Tongue 12
Malignant Neoplasm of Anterior 2/3 of Tongue Unspecified 12
Malignant Neoplasm of Tip and Lateral Border of Tongue 12
Malignant Neoplasm of Tongue, Tip and Lateral Border 12
Malignant Neoplasm of Ventral Tongue Surface Nos 12
Malignant Tumor of Anterior Two-Thirds of Tongue 12
Malignant Neoplasm of Junctional Zone of Tongue 12
Malignant Neoplasm of Mobile Part of Tongue Nos 12
Malignant Neoplasm of Ventral Surface of Tongue 12
Malignant Neoplasm of Dorsal Surface of Tongue 12
Malignant Neoplasm of Fixed Part of Tongue Nos 12
Malignant Neoplasm of Other Sites of Tongue 12
Tongue Neoplasm Malignant Stage Unspecified 12
Malignant Neoplasm of Dorsum of Tongue Nos 12
Malignant Tumor of Mobile Part of Tongue 12
Malignant Neoplasm of Dorsal Tongue Nos 12
Malignant Neoplasm of Border of Tongue 12
Malignant Neoplasm of Base of Tongue 12
Malignant Neoplasm of Lingual Tonsil 12
Malignant Tumor of Posterior Tongue 12
Malignant Neoplasm of Tongue, Nos 12
Malignant Tumor of Base of Tongue 12
Malignant Tumor of Lingual Tonsil 12
Malignant Neoplasm of Tongue Nos 12
Malignant Tumor of Tongue 12

Classifications:



Summaries for Tongue Cancer

MalaCards based summary : Tongue Cancer, also known as tongue carcinoma, is related to nasopharyngeal carcinoma and linitis plastica, and has symptoms including glossalgia An important gene associated with Tongue Cancer is MMP2 (Matrix Metallopeptidase 2), and among its related pathways/superpathways are GPCR Pathway and Cytokine Signaling in Immune system. The drugs Nicotine and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include tongue, tonsil and lymph node, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Tongue Cancer

Diseases related to Tongue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
id Related Disease Score Top Affiliating Genes
1 nasopharyngeal carcinoma 29.4 CDKN1A CDKN2A TP53
2 linitis plastica 10.3 CDH1 TP53
3 acute mountain sickness 10.3 CDKN1A TP53
4 bronchitis 10.3 CDH1 TP53
5 facio skeletal genital syndrome rippberger type 10.3 MMP2 MMP9
6 clear cell adenofibroma 10.2 CDKN2A TP53
7 gallbladder papillomatosis 10.2 CDKN1A MMP2 TP53
8 lacrimal gland adenoid cystic carcinoma 10.2 CDKN2A TP53
9 acute tricyclic antidepressant poisoning 10.2 MMP2 MMP9
10 dental caries 10.2 CDH1 MMP2 TP53
11 nasal cavity disease 10.2 CDH1 MMP2 TP53
12 pericardium leiomyoma 10.2 CDKN2A TP53
13 toxic megacolon 10.2 CDKN1A MMP9 TP53
14 adult neuronal ceroid lipofuscinosis 10.2 CDH1 MMP2 MMP9
15 maxillary neoplasm 10.2 CDH1 MMP2 MMP9
16 breast papillary carcinoma 10.2 CDH1 MMP2 MMP9
17 aminoaciduria 10.2 MMP8 MMP9
18 kleptomania 10.2 MMP2 MMP9
19 leukoencephalopathy palmoplantar keratoderma 10.2 MMP2 MMP9
20 plague 10.2 CDKN1A MMP9 TP53
21 dysembryoplastic neuroepithelial tumor 10.1 CD44 CDH1 CDKN1A TP53
22 metagonimiasis 10.1 MMP2 TP53 VEGFC
23 ideomotor apraxia 10.1 CCND1 CDH1 TP53
24 fallopian tube leiomyosarcoma 10.1 CDH1 CDKN2A TP53
25 pyomyositis 10.1 CDH1 CDKN2A TP53
26 papillary transitional carcinoma 10.1 CCND1 CDH1 TP53
27 thymus adenocarcinoma 10.1 MMP2 MMP9
28 fallopian tube adenocarcinoma 10.1 CDKN1A CDKN2A TP53
29 breast epithelioid hemangioma 10.1 CDKN1A TP53
30 spondylarthropathy 10.1 CDKN2A TP53
31 childhood-onset cerebral x-linked adrenoleukodystrophy 10.1 CDH1 CDKN2A TP53
32 mitochondrial encephalomyopathy 10.1 CDKN2A MMP2 TP53
33 paroxysmal nocturnal hemoglobinuria 10.1 CDH1 CDKN2A TP53
34 subglottis neoplasm 10.1 CDKN1A CDKN2A MMP2
35 skeletal tuberculosis 10.1 CCND1 CDKN2A
36 pituitary carcinoma 10.1 CCND1 CDH1 TP53
37 asperger syndrome 10.1 CCND1 CDH1 TP53
38 cervicitis 10.1
39 chronic monocytic leukemia 10.1 CDKN2A MMP8 TP53
40 squamous cell carcinoma of the oral tongue 10.1
41 pityriasis rosea 10.1 CDKN2A MMP8 TP53
42 breast leiomyoma 10.1 CDKN2A MMP2 TP53
43 adult medulloblastoma 10.1 CCND1 CDH1 TP53
44 spinal meninges cancer 10.1 MMP2 MMP9
45 statin toxicity 10.1 CCND1 MMP9 TP53
46 juvenile astrocytoma 10.1 MMP2 MMP9 TP53
47 benign shuddering attacks 10.1 CDH1 CDKN2A TP53
48 mixed ductal-endocrine carcinoma 10.1 MMP2 MMP8 MMP9
49 adenoid squamous cell carcinoma 10.1 CDKN2A MMP2 MMP9
50 13q12.3 microdeletion syndrome 10.1 CCND1 CDKN1A CDKN2A

Comorbidity relations with Tongue Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Tongue Cancer:



Diseases related to Tongue Cancer

Symptoms & Phenotypes for Tongue Cancer

UMLS symptoms related to Tongue Cancer:


glossalgia

MGI Mouse Phenotypes related to Tongue Cancer:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.23 CD44 CDH1 CDKN1A CDKN2A MMP2 MMP8
2 cardiovascular system MP:0005385 10.19 CCND1 CD44 CDH1 CDKN1A CDKN2A MMP2
3 cellular MP:0005384 10.18 CCND1 CD44 CDH1 CDKN1A CDKN2A MMP9
4 growth/size/body region MP:0005378 10.18 CD44 CDH1 CDKN1A CDKN2A MMP2 MMP9
5 immune system MP:0005387 10.17 CCND1 CD44 CDH1 CDKN1A CDKN2A MMP2
6 digestive/alimentary MP:0005381 10.11 CCND1 CD44 CDH1 CDKN1A CDKN2A MMP9
7 neoplasm MP:0002006 10.11 CCND1 CD44 CDH1 CDKN1A CDKN2A MMP2
8 endocrine/exocrine gland MP:0005379 10.1 CCND1 CD44 CDH1 CDKN1A CDKN2A PRLR
9 integument MP:0010771 10.01 CCND1 CD44 CDH1 CDKN1A CDKN2A MMP9
10 nervous system MP:0003631 9.97 CCND1 CD44 CDKN1A CDKN2A MMP2 MMP9
11 reproductive system MP:0005389 9.91 CCND1 CD44 CDH1 CDKN1A CDKN2A MMP9
12 respiratory system MP:0005388 9.76 CCND1 CD44 CDKN1A CDKN2A MMP2 MMP9
13 skeleton MP:0005390 9.61 CCND1 CD44 CDKN1A CDKN2A MMP2 MMP9
14 vision/eye MP:0005391 9.23 PRLR TP53 CCND1 CD44 CDKN1A CDKN2A

Drugs & Therapeutics for Tongue Cancer

Drugs for Tongue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 437-38-7 3345
3 Anesthetics Phase 4,Phase 3,Phase 2
4 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
5 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
6 Analgesics Phase 4,Phase 3,Phase 2
7 Cholinergic Agents Phase 4,Phase 2,Phase 3
8 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 2
9 Narcotics Phase 4,Phase 3,Phase 2
10 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
11 Nicotinic Agonists Phase 4
12 Analgesics, Opioid Phase 4,Phase 3,Phase 2
13 Anesthetics, General Phase 4,Phase 3,Phase 2
14 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2
15 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
16 Autonomic Agents Phase 4,Phase 2,Phase 3
17 Central Nervous System Stimulants Phase 4
18
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
19
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
20
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
21
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
22
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741 24759
23
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
24
Pilocarpine Approved Phase 2, Phase 3 54-71-7, 92-13-7 5910
25
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
26
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
27
Morphine Approved, Investigational Phase 2, Phase 3 57-27-2 5288826
28
Succinylcholine Approved Phase 3,Phase 2 306-40-1 5314
29
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
30
Doxepin Approved Phase 3 1668-19-5 667477 667468
31
Bleomycin Approved Phase 3 11056-06-7 5360373
32
Cholecalciferol Approved, Nutraceutical Phase 3 67-97-0 6221 10883523 5280795
33
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
34
Butyric Acid Experimental Phase 3 107-92-6 264
35 vitamin d Phase 3
36 Interleukin-2 Phase 3
37 Trace Elements Phase 3,Phase 2,Phase 1
38 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
40 Vitamins Phase 3,Phase 2,Phase 1
41 Anti-HIV Agents Phase 3,Phase 2
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
44 Antimetabolites Phase 3,Phase 2,Phase 1
45 Anti-Retroviral Agents Phase 3,Phase 2
46 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
47 Antimitotic Agents Phase 3,Phase 2,Phase 1
48 Micronutrients Phase 3,Phase 2,Phase 1
49 Bone Density Conservation Agents Phase 3
50 Antiviral Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 173)
id Name Status NCT ID Phase
1 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
2 Procedural Pain Treatment With Transmucosal Sublingual Fentanyl Tablet in Colonoscopy Patients Recruiting NCT01604187 Phase 4
3 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
4 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
5 Vit D3 and Omega 3 in Chemo Induced Neuropathy Unknown status NCT02294149 Phase 3
6 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3
7 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
8 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
9 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
10 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
11 Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00003139 Phase 3
12 Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study Completed NCT02714543 Phase 3
13 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Recruiting NCT00956007 Phase 3
14 Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Recruiting NCT02908477 Phase 3
15 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3
16 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3
17 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
18 Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea Active, not recruiting NCT02597478 Phase 2, Phase 3
19 Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma Not yet recruiting NCT02984410 Phase 3
20 Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma Suspended NCT00198328 Phase 3
21 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3
22 Trial of E10A in Head and Neck Cancer Unknown status NCT00634595 Phase 2
23 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2
24 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00833261 Phase 2
25 Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Unknown status NCT00851877 Phase 1, Phase 2
26 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
27 Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue Unknown status NCT00651417 Phase 2
28 Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery Completed NCT00665392 Phase 2
29 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2
30 Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer Completed NCT01084083 Phase 2
31 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
32 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2
33 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2
34 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2
35 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2
36 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2
37 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2
38 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2
39 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2
40 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed NCT01195922 Phase 1, Phase 2
41 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2
42 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2
43 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2
44 Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00423930 Phase 2
45 Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer Completed NCT00875849 Phase 2
46 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2
47 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
48 Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer Completed NCT00780312 Phase 2
49 Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies Completed NCT00845819 Phase 2
50 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Recruiting NCT03008330 Phase 1, Phase 2

Search NIH Clinical Center for Tongue Cancer

Cochrane evidence based reviews: tongue neoplasms

Genetic Tests for Tongue Cancer

Anatomical Context for Tongue Cancer

MalaCards organs/tissues related to Tongue Cancer:

39
Tongue, Tonsil, Lymph Node, Endothelial, Bone, Lung, Bone Marrow

Publications for Tongue Cancer

Articles related to Tongue Cancer:

(show top 50) (show all 470)
id Title Authors Year
1
Evidence of phenotypic stability after transduction of fluorescent proteins in two human tongue cancer cell lines. ( 28288391 )
2017
2
Effectiveness of radiotherapy+ozone on tumoral tissue and survival in tongue cancer rat model. ( 28390748 )
2017
3
Tongue-out versus tongue-in position during Intensity-Modulated Radiotherapy for base of tongue cancer: Clinical implications for minimizing post-Radiotherapy Swallowing Dysfunction. ( 28475284 )
2017
4
Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups. ( 28095396 )
2017
5
A Retrospective Evaluation of Partial Glossectomy for Early Tongue Cancer Using a Carbon Dioxide Laser. ( 28358663 )
2017
6
Swallowing Rehabilitation Affects Period of Hospitalization after Surgery for Tongue Cancer. ( 28381730 )
2017
7
Changes in the distributions of fluorine-18-labelled fluoro-2-deoxy-D-glucose accumulation into tongue-related muscles after dissection in patients with tongue cancer. ( 28467114 )
2017
8
Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. ( 28351569 )
2017
9
Contrast - enhanced ultrasound mapping of sentinel lymph nodes in oral tongue cancer - a pilot study. ( 28045344 )
2017
10
Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer. ( 28385383 )
2017
11
Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for T2-4N0 tongue cancer: control of occult neck metastasis. ( 28434836 )
2017
12
Regional recurrence in early stage I-II oral tongue cancer: a single institutional study and review of the literature. ( 28361597 )
2017
13
Immunohistochemical analysis of EGFR and hyaluronan in tongue cancer and the development of regional recurrence in patients initially diagnosed N0. ( 28355940 )
2017
14
Identification of genes associated with tongue cancer in patients with a history of tobacco and/or alcohol use. ( 28356939 )
2017
15
Maternal genetic backgrounds contribute to the genetic susceptibility of tongue cancer patients in Hunan, central of China. ( 28278694 )
2017
16
Breast Cancer in a Pectoralis Major Myocutaneous Flap Used for the Reconstruction of Tongue Cancer: A Case Report. ( 28434900 )
2017
17
Long non-coding RNA MALAT1 interacts with miR-124 and modulates tongue cancer growth by targeting JAG1. ( 28260102 )
2017
18
Nomograms to estimate long-term overall survival and tongue cancer-specific survival of patients with tongue squamous cell carcinoma. ( 28411370 )
2017
19
Targeted sequencing of tonsillar and base of tongue cancer and human papillomavirus positive unknown primary of the head and neck reveals prognostic effects of mutated FGFR3. ( 28525363 )
2017
20
Edema worsens target coverage in high-dose-rate interstitial brachytherapy of mobile tongue cancer: a report of two cases. ( 28344606 )
2017
21
Long term survival and impact of various prognostic factors in T1, T2 oral tongue cancer in Pakistan. ( 26819166 )
2016
22
Retrospective observational study of occult cervical lymph-node metastasis in T1N0 tongue cancer. ( 27889695 )
2016
23
Expression of ER stress markers (GRP78/BiP and PERK) in patients with tongue cancer. ( 27268922 )
2016
24
Mortality in tongue cancer patients treated by curative surgery: a retrospective cohort study from CGRD. ( 27994985 )
2016
25
Successful tongue cancer surgery under general anesthesia in a 99-year-old patient in Okinawa, Japan: A case report and review of the literature. ( 27588116 )
2016
26
Is an Elective Neck Dissection Necessary for All Cases of N0 Oral Squamous Cell Carcinoma? -Elective Neck Dissection may be Performed for Tongue Cancer with Tumor Thickness More than 4 mm. ( 27628601 )
2016
27
Involvement of Microglial P2Y12 Signaling in Tongue Cancer Pain. ( 27151915 )
2016
28
Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer. ( 27128434 )
2016
29
MFAP5 and TNNC1: Potential markers for predicting occult cervical lymphatic metastasis and prognosis in early stage tongue cancer. ( 27713166 )
2016
30
Quantitative Diagnosis of Tongue Cancer from Histological Images in an Animal Model. ( 27656036 )
2016
31
Development of Late Toxicities in Patients with Oral Tongue Cancer Treated with Surgical Resection and Adjuvant Radiation Therapy. ( 28123995 )
2016
32
Upregulation of PTEN suppresses invasion in Tca8113 tongue cancer cells through repression of epithelial-mesenchymal transition (EMT). ( 26649861 )
2016
33
E3 Ubiquitin ligase RNF126 regulates the progression of tongue cancer. ( 27227488 )
2016
34
Tongue cancer in the young. ( 27007019 )
2016
35
Homotypic Interaction of Stabilin-2 Plays a Critical Role in Lymph Node Metastasis of Tongue Cancer. ( 27919991 )
2016
36
Radial free forearm flap versus pectoralis major pedicled flap for reconstruction in patients with tongue cancer: Assessment of quality of life. ( 27694786 )
2016
37
Previous tonsillectomy modifies odds of tonsil and base of tongue cancer. ( 26977858 )
2016
38
Does a specimen-based margin analysis of early tongue cancer better predict local control? ( 27313090 )
2016
39
Enhancement of active MMP release and invasive activity of lymph node metastatic tongue cancer cells by elevated signaling via the TNF-I+-TNFR1-NF-I_B pathway and a possible involvement of angiopoietin-like 4 in lung metastasis. ( 27511626 )
2016
40
Predicting Radiotherapy Necessity in Tongue Cancer Using Lymph Node Yield. ( 27821247 )
2016
41
The E3 ubiquitin ligase RNF135 regulates the tumorigenesis activity of tongue cancer SCC25 cells. ( 27709798 )
2016
42
Does securin expression have significance in prognostication of oral tongue cancer? A pilot study. ( 27091335 )
2016
43
Identification and functional analysis of choline transporter in tongue cancer: A novel molecular target for tongue cancer therapy. ( 27262903 )
2016
44
microRNA-21 and microRNA-375 from oral cytology as biomarkers for oral tongue cancer detection. ( 27208839 )
2016
45
Dysphagia in Tongue Cancer Patients Before and After Surgery. ( 27126392 )
2016
46
MMP-1/2 and TIMP-1/2 expression levels, and the levels of collagenous and elastic fibers correlate with disease progression in a hamster model of tongue cancer. ( 26870168 )
2016
47
Low Pretreatment Lymphocyte-Monocyte Ratio and High Platelet-Lymphocyte Ratio Indicate Poor Cancer Outcome in Early Tongue Cancer. ( 28063763 )
2016
48
Overexpression of HMGA2 promotes tongue cancer metastasis through EMT pathway. ( 26818837 )
2016
49
MYCN-mediated miR-21 overexpression enhances chemo-resistance via targeting CADM1 in tongue cancer. ( 27055844 )
2016
50
High-dose-rate interstitial brachytherapy in early stage oral tongue cancer - 15 year experience from a tertiary care institute. ( 26985198 )
2016

Variations for Tongue Cancer

Expression for Tongue Cancer

Search GEO for disease gene expression data for Tongue Cancer.

Pathways for Tongue Cancer

Pathways related to Tongue Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 CCND1 CDKN1A CDKN2A MMP2 MMP8 MMP9
2
Show member pathways
13.32 CCND1 CD44 CDKN1A MMP2 MMP9 PRLR
3
Show member pathways
12.9 CCND1 CDH1 CDKN1A CDKN2A MMP2 MMP9
4
Show member pathways
12.71 CD44 CDH1 MMP2 MMP8 MMP9
5 12.56 CCND1 CDKN1A PRLR TP53 VEGFC
6
Show member pathways
12.53 CCND1 CDKN1A CDKN2A TP53
7
Show member pathways
12.52 CCND1 CDH1 MMP2 MMP9 TP53
8 12.47 CCND1 CDKN1A CDKN2A TP53
9
Show member pathways
12.35 CCND1 CDKN1A CDKN2A TP53
10 12.35 CCND1 CDKN1A CDKN2A TERT TP53
11
Show member pathways
12.34 CCND1 CDH1 CDKN1A TP53
12
Show member pathways
12.33 CCND1 CDKN1A CDKN2A TP53
13 12.28 CCND1 CDH1 CDKN1A CDKN2A TP53
14 12.28 BMI1 CCND1 CD44 CDKN1A CDKN2A MMP9
15 12.27 CCND1 CDKN1A CDKN2A TP53
16 12.21 BMI1 CDKN1A MMP9 TP53
17 12.19 CCND1 CD44 CDKN1A MMP2 MMP9 TP53
18 12.15 CCND1 CDH1 CDKN1A CDKN2A MMP2 MMP9
19
Show member pathways
12.06 CCND1 CDKN1A CDKN2A TP53
20 12.04 CCND1 CDKN1A CDKN2A TP53
21 12.02 CCND1 CDKN1A TERT TP53
22 12.02 CCND1 CDH1 CDKN1A MMP2 MMP9 TP53
23 12.01 CDKN1A MMP2 TP53
24 11.97 CCND1 MMP9 TP53
25 11.94 CCND1 CDKN1A CDKN2A TP53
26 11.91 CCND1 CDKN1A CDKN2A TP53
27 11.91 CCND1 CDKN1A MMP2 MMP9 TP53
28 11.9 CD44 CDH1 MMP2 MMP9
29 11.88 CCND1 MMP2 VEGFC
30
Show member pathways
11.87 MMP2 MMP8 MMP9
31 11.86 BMI1 CD44 CDKN1A CDKN2A TP53
32 11.82 CCND1 CDKN1A TP53
33 11.81 MMP2 MMP9 VEGFC
34 11.73 CDKN1A CDKN2A TP53
35 11.72 BMI1 MMP9 TERT TP53
36 11.68 CDKN1A CDKN2A MMP2 TP53
37 11.66 CCND1 CDH1 MMP2 MMP9 TERT
38 11.65 MMP2 MMP9 TERT
39
Show member pathways
11.65 CCND1 MMP2 MMP9
40 11.63 CD44 MMP2 MMP9
41 11.56 CDKN2A TP53 VEGFC
42 11.52 CCND1 CDKN1A TP53
43 11.49 CCND1 CD44 CDKN1A TP53
44
Show member pathways
11.47 CD44 MMP2 MMP9
45 11.45 CCND1 CDKN1A TP53
46 11.31 CCND1 MMP2 MMP9
47 11.27 CCND1 CDKN1A TP53
48 11.26 CCND1 CDKN1A CDKN2A MMP2 TP53
49 11.22 CCND1 CDH1 TP53
50
Show member pathways
11.05 CDKN1A CDKN2A TP53

GO Terms for Tongue Cancer

Cellular components related to Tongue Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.62 CCND1 CDKN1A

Biological processes related to Tongue Cancer according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.86 CCND1 CDH1 CDKN1A VEGFC
2 negative regulation of apoptotic process GO:0043066 9.8 CD44 CDKN1A MMP9 PRLR TERT TP53
3 negative regulation of cell growth GO:0030308 9.75 CDKN1A CDKN2A TP53
4 G1/S transition of mitotic cell cycle GO:0000082 9.71 CCND1 CDKN1A CDKN2A
5 response to organic substance GO:0010033 9.7 CCND1 CDH1 CDKN1A
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 CD44 TP53 VEGFC
7 Ras protein signal transduction GO:0007265 9.65 CDKN1A CDKN2A TP53
8 collagen catabolic process GO:0030574 9.63 MMP2 MMP8 MMP9
9 negative regulation of phosphorylation GO:0042326 9.59 CDKN1A CDKN2A
10 mammary gland alveolus development GO:0060749 9.58 CCND1 PRLR
11 embryo implantation GO:0007566 9.58 MMP2 MMP9 PRLR
12 response to corticosterone GO:0051412 9.57 CCND1 CDKN1A
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.55 CDKN1A TP53
14 endodermal cell differentiation GO:0035987 9.54 MMP2 MMP8 MMP9
15 mitotic G1 DNA damage checkpoint GO:0031571 9.49 CCND1 TP53
16 signal transduction by p53 class mediator GO:0072331 9.43 CDKN1A TP53
17 response to X-ray GO:0010165 9.43 CCND1 CDKN1A TP53
18 extracellular matrix disassembly GO:0022617 9.35 CD44 CDH1 MMP2 MMP8 MMP9
19 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.33 MMP2 MMP9 TERT
20 replicative senescence GO:0090399 8.92 CDKN1A CDKN2A TERT TP53

Molecular functions related to Tongue Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.47 BMI1 CCND1 CD44 CDH1 CDKN1A CDKN2A
2 metalloendopeptidase activity GO:0004222 9.33 MMP2 MMP8 MMP9
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CDKN1A CDKN2A

Sources for Tongue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....